Moderna coronavirus vaccine doses can be spaced up to six weeks apart but pregnant women should avoid jab, says WHO

Agency’s director of immunisation says clinical trials needed on pregnant women but there is ‘no reason to think there could be a problem’

Tom Batchelor
Tuesday 26 January 2021 15:54
Comments
UK Covid-19 vaccinations: Latest figures
Leer en Español

Moderna’s Covid vaccine can be given in two doses as much as six weeks apart, the World Health Organisation (WHO) has said. 

The WHO's Strategic Advisory Group of Experts on Immunisation, known as Sage, recommended the jab be given at an interval of 28 days but said that could be extended by a further two weeks under exceptional circumstances.

"The main recommendation for the use of this vaccine is that based on the current elements we recommend it should be given in doses of 100 micrograms or 0.5 ml with an interval of 28 days," Alejandro Cravioto, panel chair, told a virtual briefing.

"This interval might be moved to 42 days but the evidence we have does not go behond that time," he said, speaking from Mexico.

Sage also recommended the Moderna vaccine should not be used on pregnant women unless they are health workers or have conditions putting them at high risk.

This was only because clinical trials of the Moderna vaccine were needed on pregnant women,  WHO director of immunisation Kate O'Brien said.

"There is no reason to think there could be a problem in pregnancy, we are just acknowledging the data is not there at the moment," she said.

Ms O’Brien added that the WHO was "working with Moderna to go as quickly as possible" to achieve emergency use listing, allowing it to be rolled out more rapidly.

The Geneva-based health agency has given emergency use listing to just one Covid vaccine – the Pfizer BioNTech shot – so far.

A vial of the Moderna Covid-19 vaccine is seen at a local clinic as the spread of the coronavirus disease continues

On Monday, Moderna said it believed its jab would be effective against new variants that have emerged in the UK and South Africa. 

The company said it found no reduction in the antibody response against the variant found in Britain, and against the South African variant it found a reduced response but still believed its two-dose regimen would provide protection.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in